Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1/2 Study

Lignende værker

• The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia
  af: Abou Dalle, Iman, et al.
  Udgivet: (2018)
• Enasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2
  af: Dutta, Ritika, et al.
  Udgivet: (2020)
• Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib
  af: Stein, Eytan M., et al.
  Udgivet: (2019)
• Isocitrate dehydrogenase mutations in myeloid malignancies
  af: Medeiros, B C, et al.
  Udgivet: (2017)
• Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
  af: Stein, Eytan M., et al.
  Udgivet: (2017)